Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCTI CIMATEC HDT RNA Vaccine booster for COVID-19
NCT05542693Phase 2Unknown
- Sponsor
- Azidus Laboratories Limited
- Start
- Jan 2023
- Primary completion
- Mar 2023
- Modality
- Nanoparticles, mRNA Therapeutics, Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of HDT-301 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Azidus Laboratories Limited. Primary endpoints: Number of participants with a 2-fold increase or more on average by titers of neutralizing D64G pseudovirus strain (pNT50) at Day 181 and Comparison of titers generated by 5µg and 10µg doses of MCTI-CIMATEC-HDT RNA Vaccine at Day 181. Status: unknown.
02
Drugs
HDT-301
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05542693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05542693.